AACC-ACS JOINT MEETING A PROTEOMIC PREDICTOR OF LIPOPROTEIN FUNCTION AND CORONARY ARTERY DISEASE: FROM CONCEPTION TO LAUNCH

AACC-ACS JOINT MEETING
A Proteomic Predictor of Lipoprotein Function and Coronary Artery Disease: From Conception to Launch

Cory Bystrom, PhD
Translation Laboratory Director – Precision Biomarkers
Cedars Sinai Medical Center, Los Angeles

Date: Tuesday, October 1, 2019
Time: 6:00 PM Social Hour, Light Meal
7:00 PM Lecture
Location: GENESIS Kitchen + Drinks, 4242 Campus Point Ct., San Diego, CA 92121 Map
RSVP: https://aacc_oct1_bystrom.eventbrite.com

About the Speaker

Dr. Cory Bystrom serves as Translational Laboratory Director at Cedars Sinai Hospital where he is responsible for novel biomarker validation and commercialization. Prior to joining Cedars, he directed R&D at Cleveland HeartLab and commercialized a multiplex proteomic diagnostic test focusing on HDL functionality. He also has held research and development roles at Quest Diagnostics, Oregon Health Science University, Fonterra, and Pharmacia and Upjohn. Dr. Bystrom earned his PhD in chemistry from the University of Oregon and his MS and BS degrees from the University of Wisconsin.

Abstract

High-density lipoproteins are commonly used for cardiovascular risk assessment, but health depends on their functional properties, not only concentration. Cholesterol efflux capacity is one function that is associated with cardiovascular disease but its measurement is not easily realized in the clinic. I’ll describe the conception, development, validation, and evaluation of a multi-marker proteomic method and accompanying algorithms for estimation of cardiovascular disease risk. Multiple case-control studies demonstrated consistent clinical validity and the precise and saleable scalable method enables larger future studies.